(Q39533758)

12 September 2017

title

Rapid High-Performance Liquid Chromatographic Determination of Bleomycin A2 in Plasma (English)

1 reference

https://api.crossref.org/works/10.1002/JPS.2600680228

11 November 2022

main subject

pharmaceutical science

1 reference

https://api.crossref.org/works/10.1002/JPS.2600680228

11 November 2022

author name string

G. K. Shiu

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A84867

11 November 2022

T. J. Goehl

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A84867

11 November 2022

W. H. Pitlick

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A84867

11 November 2022

language of work or name

English

0 references

publication date

1 February 1979

1 reference

full work available at URL

12 September 2017

https://api.elsevier.com/content/article/PII:S002235491542489X?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1002/JPS.2600680228

https://api.elsevier.com/content/article/PII:S002235491542489X?httpAccept=text/plain

11 November 2022

1 reference

https://api.crossref.org/works/10.1002/JPS.2600680228

Journal of Pharmaceutical Sciences

11 November 2022

published in

1 reference

12 September 2017

volume

68

1 reference

12 September 2017

issue

2

1 reference

12 September 2017

page(s)

232-234

1 reference

12 September 2017

cites work

1

19

200

Umezawa

1966

1 reference

https://api.crossref.org/works/10.1002/JPS.2600680228

Phase II evaluation of bleomycin.A Southwest Oncology Group study

11 November 2022

3

1 reference

https://api.crossref.org/works/10.1002/JPS.2600680228

Phase I–II trial of intramuscularly administered bleomycin

11 November 2022

4

1 reference

https://api.crossref.org/works/10.1002/JPS.2600680228

11 November 2022

6

19

210

Umezama

1966

1 reference

https://api.crossref.org/works/10.1002/JPS.2600680228

11 November 2022

7

vol. 1

1971

1 reference

https://api.crossref.org/works/10.1002/JPS.2600680228

A clinical review of bleomycin--a new antineoplastic agent

11 November 2022

8

1 reference

https://api.crossref.org/works/10.1002/JPS.2600680228

11 November 2022

9

36

2768

Cohen

1976

1 reference

https://api.crossref.org/works/10.1002/JPS.2600680228

11 November 2022

11

20

15

Ishizuka

1967

1 reference

https://api.crossref.org/works/10.1002/JPS.2600680228

Biological studies on individual bleomycins.

11 November 2022

12

1 reference

https://api.crossref.org/works/10.1002/JPS.2600680228

Natural and artificial bleomycins: chemistry and antitumor activities

11 November 2022

13

1 reference

https://api.crossref.org/works/10.1002/JPS.2600680228

11 November 2022

15

20

149

Ichikawa

1967

1 reference

https://api.crossref.org/works/10.1002/JPS.2600680228

Microbiological assay of bleomycin: inactivation, tissue distribution, and clearance

11 November 2022

16

1 reference

https://api.crossref.org/works/10.1002/JPS.2600680228

Pharmacokinetic behaviour of bleomycin-cobalt-57 with special regard to intraarterial perfusion of the maxillo-facial region

11 November 2022

18

1 reference

https://api.crossref.org/works/10.1002/JPS.2600680228

11 November 2022

20

36

1418

Broughton

1976

1 reference

https://api.crossref.org/works/10.1002/JPS.2600680228

Reversed-phase high-performance liquid chromatography of bleomycin

11 November 2022

23

1 reference

https://api.crossref.org/works/10.1002/JPS.2600680228

11 November 2022

Identifiers

1 reference

12 September 2017

1 reference